Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

273 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-06-01

Study Completion Date

2025-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators are proposing to perform a double-blinded, non-inferiority randomized controlled trial comparing a short 30-day treatment with BZN 150mg/day (30d/150mg) vs. a 60-day treatment with BZN 300 mg/day (60d/300mg). The investigators will recruit not previously treated T. cruzi seropositive women with a live birth during the postpartum period in Argentina, randomize them at six months postpartum, and follow them up with the following specific aims:

Specific Aim 1: To measure the effect of BZN 30d/150mg compared to 60d/300mg preconceptional treatment on parasitic load measured by the frequency of positive PCR (primary outcome) and by real-time quantitative PCR (qPCR), immediately (Specific Aim 1a) and 10 months (Specific Aim 1b) after treatment.

Hypothesis 1a: The frequency of positive PCR and the parasitic load measured by qPCR immediately after BZN 30d/150mg will be non-inferior (Non Inferiority \[NI\] margin for PCR: 10% absolute difference) to BZN 60d/300mg.

Hypothesis 1b: The frequency of positive PCR and the parasitic load measured by qPCR 10 months after BZN 30d/150mg will be non-inferior (NI margin for PCR: 9% absolute difference) to BZN 60d/300mg.

Specific Aim 2: To measure the frequency of serious adverse events leading to treatment interruption of BZN 30d/150mg compared to 60d/300mg.

Hypothesis 2: The frequency of serious adverse events leading to treatment interruption will be 50% lower with BZN 30d/150mg than with BZN 60d/300mg.

A 24-month recruitment period is planned in four hospitals with 23,436 deliveries in 2015 and frequencies of T. cruzi seropositive women varying from 1.5% to 4.8%. The investigators are planning to enroll 600 T. cruzi seropositive women.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Short Benznidazole Regimen for Chronic Phase Chagas Disease Patients

NCT06339710

Chronic Chagas Disease

WITHDRAWN PHASE3

A Study of Benzathine Benzylpenicillin Intramuscular Injection in Japanese Healthy Subjects

NCT03612557

Healthy

COMPLETED PHASE1

Tinidazole for Recurrent Bacterial Vaginosis: A Pilot Study

NCT00510614

Bacterial Vaginosis

COMPLETED EARLY_PHASE1

Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

NCT00004317

Toxoplasmosis

RECRUITING PHASE4

Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia

NCT04851015

Pneumocystis Pneumocystis Pneumonia Pneumocystis Jirovecii Infection +5 more

NOT_YET_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chagas Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Placebo

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

60/300mg

The investigators will use a preparation of benznidazole (BZN) that is commercially available in Argentina: Abarax® 100mg and 50mg tablets from ELEA laboratories (Buenos Aires, Argentina). The investigators will purchase the drug at full cost.

Interventions: The standard 60d course will be 300 mg per day, which is similar to the dose used in the second phase of the BENEFIT trial. The drug will be administered orally in two doses per day: the standard course will be one 100mg and one 50mg tablet in the morning and in the evening for 60 days.

Group Type ACTIVE_COMPARATOR

Benznidazole

Intervention Type DRUG

Benznidazole tablet

30/150mg

The investigators will use a preparation of benznidazole (BZN) that is commercially available in Argentina: Abarax® 100mg and 50mg tablets from ELEA laboratories (Buenos Aires, Argentina). ELEA laboratories will prepare the placebo oral tablets, which will be identical to the drug tablets in aspect and taste. The investigators will purchase the drug and placebo at full cost.

Interventions: The BZN short course low dose scheme will be 150 mg per day for 30 days. The drug will be administered orally in two doses per day: the short course treatment will start with the active drug and then placebo oral tablet; one 100 mg tablet and one placebo tablet in the morning and one 50 mg tablet and one placebo tablet in the evening for the first 30 days. The last 30 days will be two placebo tablets in the morning and the evening.

Group Type EXPERIMENTAL

Benznidazole

Intervention Type DRUG

Benznidazole tablet

Placebo Oral Tablet

Intervention Type DRUG

Sugar pill manufactured to mimic Benznidazole

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Benznidazole

Benznidazole tablet

Intervention Type DRUG

Placebo Oral Tablet

Sugar pill manufactured to mimic Benznidazole

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Abarax Placebo (for Benznidazole)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent from the mother.
* T. cruzi seropositivity confirmed by at least two positive tests.
* Live birth.

Exclusion Criteria

* Women residing outside of the provinces of Chaco, Santiago del Estero, or Tucumán.
* Previous trypanocide treatment (BZN or nifurtimox).
* Female sterilization; no intention to use modern contraception methods during treatment.
* Positive pregnancy test.
* History of severe alcohol abuse within two years; renal insufficiency.

Minimum Eligible Age

13 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes